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Abstract
Introduction: Neuroendocrine deficiencies may affect recovery after aneurysmal subarachnoid hemorrhage (aSAH). 
Insulin like growth factor-I (IGF-I) regulates neuronal growth and apoptosis in ischemic stroke. Our study was designed 
to a) characterize the behavior of serum IGF-I and growth hormone (GH) in the acute and late phases after aSAH 
reflecting possible pituitary gland function and b) evaluate the association between IGF-I and morbidity assessed by 
Glasgow outcome scale (GOS) and health related quality of life (HRQoL) in patients with aSAH.
Methods: In this prospective cohort study, patients with aSAH (n = 30) were compared to patients who underwent 
elective aneurysm surgery (n = 16). Serum GH and IGF-I concentrations were measured daily for five (controls) or seven 
(aSAH) days and at three months. GOS and 15d HRQoL was measured at three months. A mixed models method was 
used for testing between the groups. For factors possibly affecting HRQoL in aSAH patients, we constructed a Bayesian 
predicting model using a P-course Bayesian classifier.
Results: The mean IGF-I concentrations for days one to five were 8.1 ± 3.5 nmol/l in patients with aSAH and 11.2 ± 3.1 
in the control group (P = 0.01). No corresponding difference was found at three months. Serum GH concentrations 
were similar in both patient groups. Severity of the aSAH did not affect serum IGF-I concentrations. Patients with GOS ≤ 
4 had lower IGF-I concentrations and lower HRQoL than patients with GOS 5 (P = 0.02 and 0.003 respectively). The 15d 
HRQoL was 0.81 ± 0.16 in patients with aSAH and 0.86 ± 0.09 in control patients (P = 0.24). In the Bayesian model, the 
use of statins prior to aSAH, hyponatremia, high maximal sequential organ specific score (SOFAmax), and low 
cumulative IGF-I concentrations on days one to seven were associated with poor HRQoL (accuracy 89%, sensitivity 
86%, and specificity 93%).
Conclusions: IGF-I concentrations are low during acute aSAH, which may have an impact on morbidity.
Trial registration: ClinicalTrials.gov Identifier NCT00614887
Introduction
Acute aneurysmal subarachnoid hemorrhage (aSAH) is a
devastating disease, annually affecting 9 in 100,000 peo-
ple [1]. The outcome of aSAH may be affected by major
neurological deficits and cardiovascular, endocrinologi-
cal, or psychological disorders. Neuroendocrine deficien-
cies may also affect recovery and rehabilitation after
aSAH. Endocrinological disturbances may develop
because of the proximity of the hypothalamus and hypo-
physis to sensitive vascular structures, which can be
affected by acute aSAH. Hydrocephalus, local hemor-
rhages, microinfarctions, venous stasis, vasospasm, and
surgical manipulation may also cause dysfunction of the
pituitary gland and/or hypothalamus [2].
Some studies suggest the hypothalamo-pituitary-adre-
nal (HPA) axis may already be affected in the acute phase
of aSAH [2-6]. Several studies have revealed that, at least
in the late phase, aSAH may present with a pituitary
insufficiency [2,4,7,8]. Growth hormone (GH) deficiency
is the most common single pituitary hormone deficit in
patients with traumatic brain injury (TBI) and aSAH
[4,8]. In patients with aSAH, GH deficiency may affect
the quality of life [9]. GH mediates its action via insulin-
like growth factors (IGF-I). IGF-I has potential effects on
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neuronal growth but also on neuronal cell death, apopto-
sis and neuromodulation [10-12], which play a major role
in ischemic stroke and in the pathological cellular pro-
cesses of aSAH [13]. Levels of IGF-I are low during the
acute phase of critical illness [14]. Recent studies suggest
low IGF-I levels may negatively affect outcome, at least in
patients with ischemic stroke [15-17], and low IGF-I val-
ues in patients with hemorrhagic stroke may be associ-
ated with excess mortality [17].
There is no data available on the behavior of serum
IGF-I concentrations in the acute phase of aSAH. The
aim of our study was to characterize the behavior of IGF-
I and GH acutely and three months after aSAH. This may
reflect acute pituitary function. Additionally, we hypothe-
sized that low cumulative IGF-I concentrations may neg-
atively influence morbidity assessed by Glasgow outcome
scale (GOS) and health-related quality of life (HRQoL).
Materials and methods
All patients aged 18 years or over and scheduled for an
elective open surgical aneurysm treatment (control
group), and all patients with aSAH admitted to Kuopio
University Hospital in Finland between 29 March and 30
November 30, 2006 were prospectively assessed for eligi-
bility for this study. Patients with an elective endovascular
management of their unruptured aneurysm were
excluded from the control group because of their expect-
edly short hospital stay. This study's patient population is
the same as that used in a previous publication [3]. The
exclusion criteria were: any known pituitary insufficiency,
use of etomidate before study entry or during the study
period, unknown exact bleeding day, bleeding more than
three days before inclusion, previous aSAH, and mori-
bund state of the patient.
The hospital ethics committee approved the study pro-
tocol and informed written consent was received from
the patients or their next of kin.
Patients with aSAH
The following blood samples were collected from the first
to seventh mornings following bleeding: serum (s) GH
(reference value 0 to 11.5 mU/l), serum IGF-I (reference
values: 15 to 45 nmol/l for age 21 to 30 years; 14 to 36
nmol/l for age 31 to 50 years; ages 10 to 29 nmol/l for age
51 to 70 years; and 8 to 23 nmol/l for age over 70 years).
In control patients, the corresponding blood samples
were collected from the first to fifth postoperative days
after the patients were discharged. Additional routine
laboratory parameters, such as electrolytes, were col-
lected on a daily basis.
Follow up at three months
At the scheduled three-month follow-up visit, serum GH
and serum IGF-I samples were collected at 9 am. In addi-
tion, the patients (or their relatives) were asked to fill out
a 15D quality of life questionnaire [18]. We used age-
matched and sex-matched IGF-I-concentrations as indi-
cators for low IGF-I and suspected GH deficiency. We
also used levels of IGF-I less than 11 nmol/l [19] as the
cut off for low IGF-I. Samples of serum GH and serum
IGF-I were stored at -70°C for analysis. The same person-
nel performed all analyses in one laboratory at the Kuo-
pio University Hospital. Serum GH concentrations were
analyzed with specific time-resolved fluoroimmunoassay
by AutoDelfia (PerkinElmer Life and Analytical Sciences
Wallac Oy, Turku, Finland). Serum IGF-I concentrations
were analyzed using a quantitative sandwich ELISA tech-
nique (Quantikine Human IGF-1 Immunoassay; R&D
Systems, Minneapolis, MN, USA).
Quality of life assessment
The HRQoL was measured by the 15D scale [18,20]. The
15D is a generic and standardized HRQoL instrument
consisting of 15 dimensions: mobility, vision, hearing,
breathing, sleeping, eating, speech, elimination, usual
activities, mental functioning, discomfort and symptoms,
depression, distress, vitality, and sexual activity. Each
dimension has five grades of severity. For each dimen-
sion, the respondent must choose one of the five levels
that best describes his or her state of health at the
moment (best level = 1; worst level = 5). The results of
15D can be presented as a single index or as a profile of all
15 dimensions. A change of 0.02 to 0.03 points in the
health utility index or 15D score is considered to be clini-
cally noteworthy. The values on a 0 to 1 scale reflect the
levels of the dimension, with 1 corresponding to no prob-
lems with the dimension and 0 to being dead. The mean
score of the Finnish population aged 50 to 59 years was
0.92 (0.91 to 0.92) [21]. In this study, HRQoL-indexes
were classified into three groups: 0.8 to 1.0 = normal, 0.6
to 0.79 = limited, and less than 0.6 = poor HRQoL.
Statistical methods
We used a power of 80% and a two-sided α-level of 0.05 in
sample size calculations. We assumed that 25% of
patients with aSAH and none of the elective surgical
patients would develop pituitary insufficiency measured
by low IGF-I. Data are presented as mean ± standard
deviation, absolute values and percentages, or medians
and interquartile ranges. Distribution of the data was
assessed by the Kolmogorov-Smirnov test. For normally
distributed parameters, student's t-tests were used to
compare the means of different groups. The Mann-Whit-
ney U test was used for nonparametric testing between
the groups. A mixed models method was used to test
between groups, allowing heterogeneity between the
groups. To identify the factors associated with poor
HRQoL or death, we used a Bayesian predicting model inBendel et al. Critical Care 2010, 14:R75
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aSAH patients. This was performed using P-course
Bayesian classifier [22].
P-course is a web-based Bayesian classifier that is able
to use multidimensional priors, for example separate pri-
ors for the outcome variable, in general, and for the out-
come variable according to each predicting variable. The
methods have equaled or outperformed novel logistic
regression, especially in small data sets, in terms of pre-
diction accuracy [23], variable selection, and multiple
performance measures. They can perform well with
incomplete or complex data typical to small data sets.
Modeling of this data was made without informative a
priori information.
The outcome variable was poor HRQoL measured by
15D and dichotomized into normal (0.80 to 1.00) or poor
(0 to 0.79), where the value 0 indicated death. In the first
phase, there were 355 potential predicting variables. By
using P-course classifier, this was reduced to 22 variables
from 30 aSAH patients. To avoid over-fitting the model,
we formed four randomly selected sets of 25 patients, and
a prediction model was performed for each set. We
obtained four slightly different sets of prediction vari-
ables.
Results
We recruited 30 patients with aSAH and 16 control
patients who underwent elective aneurysm surgery. We
were unable to recruit the planned 30 control patients
because endovascular aneurysm treatment was fre-
quently chosen [3]. Demographic patient data are pre-
sented in Table 1.
Seventeen patients with aSAH underwent endovascular
treatment and 13 patients had open surgery. The mean
length of stay (LOS) was 97 ± 100 hours at the ICU and
34 ± 51 hours at the high-dependency unit (HDU) in
patients with aSAH. Patients in the control group had an
HDU LOS of 22 ± 2 hours. Patients with aSAH had a hos-
pital LOS of 14.6 ± 5.4 days, and patients in the control
group of 8 ± 3 days (P < 0.001). The three-month mortal-
ity was 10% in patients with aSAH. None of the patients
in the control group died.
Serum IGF-I concentrations are presented in Figure 1.
IGF-I levels were significantly lower in patients with
aSAH than in control patients on days one to five (P =
0.01), but no difference was found at three months follow
up (Table 2). The mean IGF-I concentration for days one
to five was 8.1 ± 3.5 nmol/l in patients with aSAH and
11.2 ± 3.1 in the control group. Serum GH concentrations
were similar in patients with aSAH and control patients.
Serum GH and IGF-I did not correlate at any time point
in patients with aSAH or in the control group.
Figure 2 represents the pooled distribution of IGF-I in
respect to different cut-off levels.
No statistically significant differences were found in the
proportion of having lower than age-related IGF-I refer-
e n c e  v a l u e s  b e t w e e n  p a t i e n t s  w i t h  a S A H  o r  c o n t r o l s .
Hunt and Hess grade, Fisher grade, and the presence of
hydrocephalus or vasospasm were not associated with
the level of IGF-I concentration, either less than 11 nmol/
l or more than 11 nmol/l.
In patients with aSAH, there were no differences in
IGF-I or GH concentrations between the patients with
respect to aneurysm location (anterior communicating
artery versus others), treatment modality (clip vs. coil),
Hunt-Hess grades (I to III versus IV to V), Fisher grade (I
to II versus III to IV), Glasgow Coma Scale (GCS) (less
than 8 or more than 8), symptomatic vasospasm and/or
need for norepinephrine (n = 9), or hydrocephalus on
admission. Gender or body mass index did not affect
IGF-I or GH concentrations. Age was negatively corre-
lated with IGF-I (r = -0.31, P ≤ 0.001).
The mean 15D HRQoL sum in patients with aSAH was
0.81 ± 0.16 and in control patients 0.86 ± 0.09 (P = 0.24).
Quality of life was moderately low (<0.8) in six patients
with aSAH and in five control patients (P = 0.75). In addi-
tion, three patients with aSAH and none of the control
patients had poor quality of life (<0.6). The HRQoL
dimensions of speech (P = 0.04) and eating (P = 0.03)
were lower in patients with aSAH than in the control
group; otherwise, no statistically significant differences
were observed in the scores between the groups. Ten
patients in the aSAH group had a GOS of four or less, and
the others had a GOS of five. Patients with a GOS of four
or less had lower quality of life than patients with a GOS
of five (0.7 vs.0.88, P = 0.003). Additionally, patients with
a GOS of four or less had lower mean IGF-I concentra-
tions than patients with a GOS of five (8.3 ± 2.6 nmol/l vs.
12.7 ± 5.1 nmol/l, P = 0.02). Patients with Hunt & Hess
grades IV to V had similar HRQoL than patients with
Hunt & Hess grades I to III (0.73 ± 0.2 vs. 0.84 ± 0.13, P =
0.12). aSAH patients with low HRQoL (<0.8) had lower
mean IGF-I concentrations than patients with good
HRQoL (5.7 ± 2.1 nmol/l vs. 8.7 ± 3.4 nmol/l). Mean IGF-
I for days one to seven was mildly associated with HRQoL
by a Pearson's correlation coefficient of 0.36 (P = 0.08).
In the Bayesian model, use of statins prior to aSAH,
hyponatremia, high maximal sequential organ specific
score, and the sum of IGF results for days one to seven
after the aSAH were associated with poor HRQoL. This
model was accurate in 78.6% of cases in leave-one-out
cross validation (corresponding log-score 0.57, compared
with 53.6% accuracy for the biggest class (i.e., default or
educated guess), log-score 0.69). When the model was
tested by putting the total material into the model, an
accuracy of 89% was reached. The sensitivity was 0.86
and specificity was 0.93. The results indicate that a lowBendel et al. Critical Care 2010, 14:R75
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IGF level in the days following aSAH may be associated
with poor HRQoL or death.
Discussion
To the best of our knowledge, this is the first study to
evaluate the behavior of IGF-I in the acute phase of
aSAH, and to combine it with GOS and HRQoL assess-
ment at three months. According to our study, serum
IGF-I levels are low during acute aSAH, but they normal-
ize at three months. The results may reflect diminished
acute pituitary function. The severity of aSAH does not
influence serum IGF-I levels. Quality of life at three
months was equal in patients with acute alive aSAH at
three months and patients who underwent elective sur-
gery for unruptured aneurysms. However, low IGF-I val-
ues, measured acutely after aSAH, may predict morbidity
assessed by GOS and HRQoL.
aSAH may cause various long-lasting neurological defi-
cits and disturbances in mental health, sleep, concentra-
tion capability, anxiety, and depression [24]. These
s y m p t o m s  a r e  t h o u g h t  t o  b e  c a u s e d  b y  a S A H - r e l a t e d
ischemic lesions. There is some evidence showing pitu-
itary function deficits may affect quality of life years after
aSAH [9]. A GH deficiency might adversely affect vitality,
sleep, and fatigue dimensions of quality of life. Although
the mean quality of life was similar in patients with aSAH
and control patients, patients with aSAH had depressed
quality of life in eating and speech. Those aSAH patients
with cumulative low IGF-I concentrations are at risk for
low quality of life and increased morbidity, which may
support the theory of the imperative role of IGF-I in the
acute phase of neurological brain injury [15]. The role of
IGF-I in the recovery of aSAH is not well studied; how-
ever, it is known that aSAH causes various long-lasting
deficits in quality of life [24]. In our study, we found an
association between IGF-I and HRQoL and hypothesize,
but cannot demonstrate, that this is causal.
Table 1: Patient demographics
aSAH
Clipped
(n = 13)
aSAH
Coiled
(n = 17)
P value for 
clipped vs. 
coiled
Control (n = 16) P value for aSAH vs. 
controls
Age, years (range) 50 (25-73) 54 (21-78) 0.53 50 (37-64) 0.53
Gender M/F 5/8 9/8 0.41 4/12 0.15
Aneurysm 
location
ICA 2 4 6
MCA 8 0 10
ACoA 1 10 0
ACA distal 1 1 0
VBA 1 2 0
Hydrocephalus at 
admission
24 0
Fisher grade
I-II 2 2
III-IV 11 15
Hunt and Hess 
initial
I-II 5 10
III 3 3
IV-V 5 4
SAPS II 27 ± 12 33 ± 14 0.27
APACHE II 14 ± 5 16 ± 6 0.53
Data are presented as numbers or mean ± standard deviation unless otherwise indicated.
aSAH clipped, patients with their ruptured aneurysm treated by open surgical clipping, aSAH coiled, patients with their ruptured aneurysm 
treated by endovascular coiling. ACA, anterior cerebral artery; AcoA, anterior communicating artery; APACHE, Acute Physiology and Chronic 
Health Evaluation; ICA, internal carotid artery; MCA, median cerebral artery; SAH, subarachnoid hemorrhage; SAPS, Simplified Acute 
Physiology Score; VBA, vertebro basilar artery.Bendel et al. Critical Care 2010, 14:R75
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In the context of aSAH, it is most interesting that IGF-I
presents with major vascular effects, and thus may con-
tribute to the pathophysiological processes in aSAH [25].
Serum IGF-I is essential in mediating GH action. Dur-
ing critical illness, serum levels of IGF-I may decrease
substantially [14]. There is increasing evidence that IGF-I
has an essential role in neuronal growth, regeneration,
and apoptotic cell death, and in adaptation to brain isch-
emia [10-12,15]. All these mechanisms may also be
involved in acute aSAH [13]. In ischemic stroke, as well as
meningococcal sepsis, low IGF-I concentrations may pre-
dict poor outcome in humans [15,26]. Surgical stress and
Figure 1 Serum IGF-I concentrations in patients with aSAH and in the control group. P = 0.01 for the difference between groups on days one 
to five and P = 0.9 at three months. Data are presented as median, interquartile ranges, and outliers. For more detailed numbers see Table 2. aSAH, 
aneurysmal subarachnoid hemorrhage; IGF-I, insulin like growth factor-I.
day 1  day 2  day 3  day 4  day 5  3 months 
Table 2: GH and IGF-I concentrations at different time points
GH (mU/l) IGF-I (nmol/l)
aSAH Control P value aSAH Control P value
day1 3.4 ± 5.5 1.6 ± 2.7 0.18 8.2 ± 3.1 10.5 ± 2.7 0.04
day2 3.5 ± 5.5 4.5 ± 5.3 0.48 8.4 ± 3.6 11.9 ± 3.1 <0.01
day3 3.0 ± 5.3 1.8 ± 1.6 0.37 8.1 ± 4.2 11.4 ± 4.2 <0.01
day4 2.4 ± 4 3.5 ± 4.5 0.54 7.8 ± 3.9 10.9 ± 3.8 0.01
day5 2.0 ± 2.1 2.4 ± 3.7 0.72 8.0 ± 4.4 11.1 ± 4.1 <0.01
day6 2.1 ± 2.4 7.8 ± 4.0
day7 1.6 ± 2.4 7.7 ± 4.0
3 months 2.0 ± 5.1 3.7 ± 5.0 0.23 9.7 ± 3.1 10.4 ± 2.4 0.9
Data are presented as mean values ± standard deviations.
aSAH, aneurysmal subarachnoid hemorrhage;GH, growth hormone; IGF-I: Insulin like growth factor-I.Bendel et al. Critical Care 2010, 14:R75
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brain manipulation in the control group were not associ-
ated with a decrease in IGF-I concentrations, as in
patients with aSAH, regardless of the severity. Several
factors other than GH secretion, for example nutritional
status, may affect IGF-I concentrations [27]. Therefore,
low IGF-I is not always associated with GH deficiency per
se [28].
Low IGF-I concentrations in aSAH may reflect either
pituitary GH insufficiency, decreased liver production, or
a stress-related decrease of IGF-I concentrations in criti-
cal illness. An essential percentage of aSAH patients had
IGF concentrations far below the age-related reference
values. It was shown previously that a disturbance in the
function of the GH-IGF axis is the first pituitary defi-
ciency to appear after aSAH or TBI [4,29]. The mecha-
nisms are not fully understood, but the vulnerable and
complex vasculature of the pituitary gland may easily be
affected by severe brain insults.
The role of single IGF-I concentration measurement
may be controversial. It is generally accepted that defini-
tive GH insufficiency should be tested by means of a
stimulation test [30]. Concentrations of IGF-I less than 10
nmol/l have a specificity of 95%, but a sensitivity of only
40% in diagnosing GH deficiency [31]. In our study, the
IGF-I concentrations were often far lower than this
threshold. There are numerous cut-off points for IGF-I in
screening for GH deficiency [19,28,32]. However, it is not
known how high concentrations of IGF-I could be neuro-
protective in acute intracranial neurological catastrophes.
In our study, GH concentrations and IGF-I concentra-
tions did not correlate with each other. GH concentra-
tions vary a lot during critical illness; the pulsatile
secretion of GH makes adequate interpretation of serum
concentrations of GH especially difficult. In the present
study, GH concentrations were equal in patients with
aSAH and the control patients. In the literature, there are
no data on GH concentrations in the acute phase of
aSAH. At the later phase, after aSAH, GH insufficiency
may appear in 25% of patients [4].
There are some limitations in our study. We did not use
the GH stimulation test when diagnosing GH deficiency.
However, as described above, IGF-I itself has an essential
role in acute neurological diseases [11,12]. The method
used for measuring IGF-I may also influence the results
[27]. Although our sample size was small, the aSAH was
well defined by the onset and type of bleeding. The con-
trol group may be criticized because it consisted of
patients undergoing open cranial surgery; that is, patients
exposed to similar kinds of stress as those with aSAH.
However, using other ICU patients as the control group
might have caused other confounding factors, such as
infections and hemodynamic instability.
W e  p r o p o s e  t h a t  i t  m i g h t  a l s o  b e  a r g u e d  t h a t  t h e
method of securing the ruptured aneurysm in the aSAH
group could markedly effect the results. However, sever-
ity of the bleeding and the level of consciousness on
admission are by far the most important prognostic fac-
tors in aSAH and the treatment modality is of lesser
importance [33,34]. As expected, there were no differ-
ences in IGF-I or GH concentrations between the
patients with respect to treatment modality. If surgery
had an effect, the surgical patients in the control would
compensate this effect on IGF-I in comparisons between
the control and aSAH groups.
IGF-I may be one factor among multiple others in
influencing outcome in patients with aSAH. Larger stud-
ies are needed to prove the causality of this finding.
Conclusions
Serum IGF-I concentrations are low in patients with
acute aSAH, which may affect morbidity in these
patients. The severity of aSAH did not affect IGF-I con-
centrations. Larger studies are needed to evaluate the
neuroprotective role of IGF-I in aSAH.
Key messages
• IGF-I has an important role in neuronal growth and
cell death
• Serum IGF-I concentrations are low in the acute
phase of aSAH
• Low IGF-I concentrations may reflect acute pitu-
itary insufficiency in patients with aSAH
Figure 2 Pooled IGF-I concentrations in patients with aSAH and 
in the control group. The line represents the cut-off level of 11 nmol/
l. The insulin like growth factor-I (IGF-I) concentration was below 11 
nmol/l on day one in 77% of aneurysmal subarachnoid hemorrhage 
(aSAH) patients and in 23% (P = 0.02) of control patients. The respective 
values were 74% and 27% (P = 0.05) on day two, 70% and 30% (P = 0.3) 
on day three, 72% and 28% (P = 0.22) on day four, and 74% and 27% (P 
= 0.05) on day five. In the aSAH group, 83% of patients on day six and 
76% on day seven had IGF-concentrations below 11 nmol/l. At three 
months, no patient had IGF-concentrations lower than 11 nmol/l.Bendel et al. Critical Care 2010, 14:R75
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• Low IGF-I concentrations may affect morbidity in
patients with aSAH
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